The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial. In patients with HER2 ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

In addition, HER2 activation can activate Ras/Raf and MEK pathways, which favors cancer cells’ growth and migration. Trastuzumab has been proposed to trigger HER2 internalization and degradation ...

These participants were randomly assigned to treatment with either a combination of the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) (TP) every three weeks or a standard EGFR ...

Get Instant Summarized Text (Gist) Trastuzumab emtansine (T-DM1) significantly improves long-term survival in high-risk HER2-positive breast cancer patients post-surgery, reducing the risk of ...

Pts with event, n (%) 198 (54.7) 20 (58.8) ...

both receptors negative or unknown); preoperative HER2-directed therapy (trastuzumab alone vs. trastuzumab plus an additional HER2-directed agent); and pathological nodal status after neoadjuvant ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer. HealthDay News — For patients with human epidermal growth factor receptor ...

after a first course of chemotherapy and dual blockade and HER2 blockade with pertuzumab [Perjeta]/trastuzumab [Herceptin], usually treat with the maintenance treatment with pertuzumab/trastuzumab ...

test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow classification allows identification of ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...